Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report

Autor:	Russell Gollard, Bill Arana, Erin Kaltenbrun, Paul Tebbey
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	non-small-cell lung cancer nivolumab cancer vaccine pd-l1 checkpoint inhibition Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Case Reports in Oncology, Vol 16, Iss 1, Pp 440-446 (2023)
Druh dokumentu:	article
ISSN:	1662-6575
DOI:	10.1159/000530132
Popis:	Checkpoint inhibitors (CIs) are now standard of care for late-stage non-small-cell lung cancer (NSCLC); however, only a minority of patients treated with a CI show clinical benefit compared to platinum-based chemotherapy alone, regardless of programmed cell death ligand 1 (PD-L1) expression levels. We describe a case of durable tumor response and disease stabilization in a patient with advanced pretreated squamous NSCLC given a maintenance treatment comprised of nivolumab, docetaxel, and ramucirumab combined with the allogeneic cellular cancer vaccine viagenpumatucel-L over a period of 28 months. Our case suggests that combination strategies that serve to sensitize tumors to checkpoint inhibition, even in patients refractory to available treatment, may lead to improved efficacy.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/c073b8672bd74df380eeb6911c75f383 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.